tradingkey.logo
tradingkey.logo
Buscar

Precigen Inc

PGEN
Añadir a la lista de seguimiento
5.250USD
-0.450-7.89%
Cierre 07/01, 16:00ETCotizaciones retrasadas 15 min
1.87BCap. mercado
PérdidaP/E TTM

Más Datos de Precigen Inc Compañía

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Información de Precigen Inc

Símbolo de cotizaciónPGEN
Nombre de la empresaPrecigen Inc
Fecha de salida a bolsaAug 08, 2013
Director ejecutivoSabzevari (Helen)
Número de empleados143
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 08
Dirección20374 Seneca Meadows Parkway
CiudadGERMANTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20876
Teléfono13015569900
Sitio Webhttps://precigen.com/
Símbolo de cotizaciónPGEN
Fecha de salida a bolsaAug 08, 2013
Director ejecutivoSabzevari (Helen)

Ejecutivos de Precigen Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.77M
+3.47%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
202.10K
+45.27%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
139.37K
+23.12%
Mr. Randal Joe Kirk
Mr. Randal Joe Kirk
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.77M
+3.47%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Precigen Inc?

Los cinco principales accionistas de Precigen Inc son: Dr. Helen Sabzevari, Ph.D.

¿Cuántas instituciones poseen acciones de Precigen Inc (PGEN)?

A fecha de 2026Q1, 355 instituciones poseen acciones de Precigen Inc, con un valor de mercado combinado de aproximadamente 270.08M, lo que representa el 75.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 16216262.00.

¿Cuál es la mayor fuente de ganancias de Precigen Inc?

El 2026Q1, el segmento empresarial Product generó la ganancia más alta para Precigen Inc, ascendiendo a 3.98M y representando el 41.05% de la ganancia total.